The stock has a 36-month beta value of 1.17. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for RXST is 38.27M, and at present, short sellers hold a 5.96% of that float. On January 31, 2025, the average trading volume of RXST was 738.28K shares.
RXST) stock’s latest price update
RxSight Inc (NASDAQ: RXST)’s stock price has plunge by 4.05relation to previous closing price of 31.58. Nevertheless, the company has seen a 1.39% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-12 that ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) — (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance.
RXST’s Market Performance
RxSight Inc (RXST) has experienced a 1.39% rise in stock performance for the past week, with a -3.97% drop in the past month, and a -34.61% drop in the past quarter. The volatility ratio for the week is 3.48%, and the volatility levels for the past 30 days are at 5.39% for RXST. The simple moving average for the past 20 days is 0.50% for RXST’s stock, with a -33.29% simple moving average for the past 200 days.
Analysts’ Opinion of RXST
Many brokerage firms have already submitted their reports for RXST stocks, with Stifel repeating the rating for RXST by listing it as a “Hold.” The predicted price for RXST in the upcoming period, according to Stifel is $40 based on the research report published on December 20, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see RXST reach a price target of $42, previously predicting the price at $56. The rating they have provided for RXST stocks is “Equal Weight” according to the report published on December 11th, 2024.
UBS gave a rating of “Buy” to RXST, setting the target price at $52 in the report published on December 06th of the previous year.
RXST Trading at -12.35% from the 50-Day Moving Average
After a stumble in the market that brought RXST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.62% of loss for the given period.
Volatility was left at 5.39%, however, over the last 30 days, the volatility rate increased by 3.48%, as shares sank -2.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.59% lower at present.
During the last 5 trading sessions, RXST rose by +1.39%, which changed the moving average for the period of 200-days by -40.34% in comparison to the 20-day moving average, which settled at $32.70. In addition, RxSight Inc saw -4.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RXST starting from Maniar Shweta, who sale 3,519 shares at the price of $30.87 back on Jan 22 ’25. After this action, Maniar Shweta now owns 7,383 shares of RxSight Inc, valued at $108,618 using the latest closing price.
Maniar Shweta, the Director of RxSight Inc, proposed sale 3,519 shares at $30.87 during a trade that took place back on Jan 22 ’25, which means that Maniar Shweta is holding shares at $108,618 based on the most recent closing price.
Stock Fundamentals for RXST
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.63 for the gross margin
The net margin for RxSight Inc stands at -0.22. The total capital return value is set at -0.14. Equity return is now at value -13.99, with -12.47 for asset returns.
Based on RxSight Inc (RXST), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -2.0. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -1861.0.
Currently, EBITDA for the company is -41.04 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 9.53. The receivables turnover for the company is 5.46for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.67.
Conclusion
To sum up, RxSight Inc (RXST) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
